Reason: $MRNA closed Friday, October 9 at its 52-week high, up 14.21% on the day and 18.41% on the week, overbought and 209.8% above its 200-day; no cause is on file for Friday's move. $AMGN turned from pullback back to uptrend, $TMO is steady, $VRTX is basing above its 200-day, and $CRSP sits on its 200-day with a negative year and negative alpha.

Price/RSI Table

As of 2026-10-09. Status reads the 200-day trend first and RSI second; Action is a trend-hold lens: an extended name is never an entry, and a name below its 200-day with a negative year is not a dip.

What Changed Since 2026-10-02

• MRNA: moves from intact to extended. Friday's 14.21% gain has no cause on file: its news was last pulled September 30, so news was not pulled for this move; no October 9 captures; stock-events checked. It also rose 4.81% on October 7, cause unknown per that day's market brief. RSI above 70 at the high is not an entry.
• AMGN: back to a strong-up short-term trend from last week's pullback, up 2.94% on the week, 13.2% above its 200-day on a +40.43% year.
• VRTX: still basing, with a weak short-term trend, 7.4% above its 200-day on a +22.95% year. The only dated item in its October 8 news pull is an RBC target raise to $576 from $570 (Markets Insider).
• TMO: flat week inside an intact trend.
• CRSP: rose 5.85% Friday (cause not on file; news last pulled September 22, so not pulled for this move) but fell 3.68% on the week. It is 0.3% above its 200-day on a −28.74% year with negative alpha: the broken one in the group.
• Roster unchanged since October 2: no entrants, no dropouts.

Watch

MRNA needs to reset from overbought into a flag before it is a setup. CRSP's 200-day is the line. Thermo Fisher is scheduled to report on October 21, the first read on tool orders.

Sources

• Tape data (price, RSI, returns, one-year change, distance to the 200-day): pre-computed summaries as of the 2026-10-09 settled close, summaries (Massive/Polygon).
• Prior edition (format and roster only): 2026-10-02-biotech.
• Event checks: research/stock-events/ (nothing dated October 5-9 for these names; TMO October 21 report scheduled), the 2026-10-05 through 2026-10-08 market briefs under research/issues/, research/capture/ for October 5-9 (no October 9 article or social captures on file; Moderna and CRISPR Form 4 filings only); news receipts under stocks/news/latest.json` (VRTX and TMO pulled 2026-10-08; AMGN 2026-10-07; MRNA 2026-09-30; CRSP 2026-09-22).
• Primary link: Markets Insider, Vertex price target raised at RBC — https://markets.businessinsider.com/news/stocks/vertex-pharmaceuticals-price-target-raised-to-576-from-570-at-rbc-capital-1036610255.